• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    RenovoRx Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/25/25 5:17:08 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RNXT alert in real time by email
    false 0001574094 0001574094 2025-06-25 2025-06-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 25, 2025 (June 24, 2025)

     

    RENOVORX, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-40738   27-1448452

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    2570 W. El Camino Real, Ste. 320

    Mountain View, CA

          94040
    (Address of principal executive offices)       (Zip Code)

     

    Registrant’s telephone number, including area code: (650) 284-4433

     

    N/A

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.0001 par value per share   RNXT   Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    On June 24, 2025, RenovoRx, Inc., a Delaware corporation (the “Company”), held its 2025 annual meeting of stockholders (the “Annual Meeting”). The number of shares of common stock of the Company entitled to vote at the Annual Meeting (the “Voting Stock”) was 36,551,752 shares outstanding as of April 25, 2025 (the “Record Date”). No other shares of the Company’s capital stock were entitled to vote at the Annual Meeting. The number of shares of Voting Stock present or represented by valid proxy at the Annual Meeting was approximately 20,086,518 shares of Voting Stock, constituting a quorum. At the Annual Meeting, the Company’s stockholders voted on the following three proposals:

     

    Proposal 1 – Director Election Proposal

     

    At the Annual Meeting, the Company’s stockholders elected each of Shaun R. Bagai, Ramtin Agah, M.D., Kirsten Angela Macfarlane, Laurence J. Marton, M.D., Una S. Ryan, O.B.E., Ph.D., D.Sc., and Robert J. Spiegel, M.D., FACP as a director for a one-year term that expires at the Company’s 2026 annual meeting of stockholders or until a successor is duly elected and qualified, subject to his or her earlier death, removal or resignation. The voting results were as follows:

     

    Nominee 

    Votes

    For

      

    Votes

    Withheld

       Broker Non-Vote  
    Shaun R. Bagai   13,033,638    98,620    6,954,260  
    Ramtin Agah, M.D., FACP   13,055,807    76,451    6,954,260  
    Kirsten Angela Macfarlane   13,044,334    87,925    6,954,259  
    Laurence J. Marton, M.D.   9,815,887    3,316,371    6,954,260  
    Una S. Ryan, O.B.E., Ph.D., D.Sc.   9,522,909    3,609,349    6,954,260  
    Robert J. Spiegel, M.D., FACP   9,857,399    3,274,859    6,954,260  

     

    Proposal 2 – Incentive Plan Amendment Proposal

     

    The Company’s stockholders voted to approve two amendments to the Company’s Amended and Restated 2021 Omnibus Equity Incentive Plan (the “2021 Plan”), specifically (i) the addition of 913,794 shares of common stock of the Company, which is equal to 2.5% of total issued and outstanding shares of the Record Date, to the total number of shares of common stock reserved and available for issuance under the 2021 Plan and (ii) an increase in the 2021 Plan’s “evergreen” provision to increase the size of the 2021 Plan each year from three percent (3%) of shares outstanding on the final day of the immediately preceding calendar year to five percent (5%). The voting results were as follows:  

     

    Votes For   Votes Against   Abstentions   Broker Non-Votes 
     9,056,181    4,037,698    38,379    6,954,260 

     

    Proposal 3 – Auditor Ratification Proposal

     

    The Company’s stockholders voted to ratify the appointment by the audit committee of the Board of directors of the Company of Frank, Rimerman + Co. LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025. The voting results were as follows:

     

    Votes For   Votes Against   Abstentions   Broker Non-Votes 
     19,131,750    949,070    5,698    0 

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      RENOVORX, INC.
         
    Dated: June 25, 2025 By: /s/ Shaun R. Bagai
      Name: Shaun R. Bagai
      Title: Chief Executive Officer

     

     

     

    Get the next $RNXT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $RNXT

    DatePrice TargetRatingAnalyst
    11/1/2021$16.00Buy
    Roth Capital
    10/6/2021$15.00Buy
    Maxim Group
    More analyst ratings

    $RNXT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Agah Ramtin bought $29,400 worth of shares (21,000 units at $1.40), increasing direct ownership by 3% to 734,460 units (SEC Form 4)

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      6/9/25 6:03:27 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Agah Ramtin bought $13,500 worth of shares (15,000 units at $0.90), increasing direct ownership by 1% to 1,113,460 units (SEC Form 4)

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      4/17/25 6:10:32 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Bagai Shaun bought $6,821 worth of shares (7,500 units at $0.91), increasing direct ownership by 2% to 320,040 units (SEC Form 4)

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      4/16/25 6:08:22 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    SEC Filings

    See more
    • SEC Form S-8 filed by RenovoRx Inc.

      S-8 - RenovoRx, Inc. (0001574094) (Filer)

      6/27/25 4:11:01 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RenovoRx Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - RenovoRx, Inc. (0001574094) (Filer)

      6/25/25 5:17:08 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by RenovoRx Inc.

      10-Q - RenovoRx, Inc. (0001574094) (Filer)

      5/15/25 4:15:48 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Leadership Updates

    Live Leadership Updates

    See more
    • RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

      LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships. Mr. Witt's appointment highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities not only for its RenovoGem™ investigational combination product (currently in Phase III clinical development), but also opportunities with the Company's foundational FDA

      6/10/24 8:30:00 AM ET
      $IMMX
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RenovoRx Closes $6.1 Million Private Placement

      With Material Participation From Insiders, Offering Proceeds to Help Drive Company Towards Second Interim Analysis of the Pivotal TIGeR-PaC Phase III Clinical Trial by Late 2024 RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that it has closed a private placement (the "private placement" or the "financing") resulting in gross proceeds of approximately $6.1 million, before deducting offering expenses. The closing of this private placement extends RenovoRx's cash runway as RenovoRx continues its ongoing pivotal TIGeR-PaC Phase III c

      1/29/24 8:30:00 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.

      RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Michel Ducreux, M.D., Ph.D. to the Company's Scientific Advisory Board (SAB). Dr. Ducreux is the Head of the Gastrointestinal Oncology Unit and Gastrointestinal Oncology Tumor Board at Gustave Roussy, Professor of Oncology at Paris-Saclay University in France, and Vice-Chair of ESMO GI. Dr. Ducreux was trained in medicine, gastroenterology, and gastrointestinal tract oncology at the University of Paris Sud. Dr. Ducreux earned his master's degree in biological sciences and PhD in health sciences. He has held pre

      11/16/23 8:35:00 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

      Q1 2025 RenovoCath® Revenues of ~$200,000, Exceeding Expectations and Anticipated to Continue Growing Sequentially with New Customer Purchase Orders and Reorders Cash on Hand of $14.6 Million Anticipated to Fully Fund both RenovoCath Commercialization Scale-up and Continued Progress Towards the Completion of the Ongoing Phase III TIGeR-PaC Clinical Trial Completion of the TIGeR-PaC Clinical Trial Enrollment and Review of Second Interim Analysis by Data Monitoring Committee on Target for 2025 Company to Host Conference Call at 4:30 p.m. ET RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializ

      5/15/25 4:05:00 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

      RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath©, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer, Shaun Bagai, will participate in a fireside chat at the Alliance Global Partners (A.G.P.) Virtual Healthcare Company Showcase hosted by Scott Henry, Managing Director and Healthcare Analyst at A.G.P., on May 21, 2025. Mr. Bagai will share recent business developments, highlighting continuing momentum with the Company's RenovoCath commercialization, as well as progress in the ongoing Phase III TIGeR-PaC clinical trial. TIGeR-PaC is evaluat

      5/14/25 8:30:00 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

      Patent Expands Protection of TAMP therapy platform, Including Methods to Deliver an Agent, such as a Chemotherapeutic Drug, Near a Tumor RenovoRx Currently Holds a Strong and Growing IP Portfolio with 19 Issued Patents and 12 Pending Patents Supporting the Commercialization of RenovoCath Device RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that it has received an Issue Notification from the U.S. Patent and Trademark Office (USPTO) indicating that U.S. patent NO. 12,290,564, becomes effective today, May 6, 2025.

      5/6/25 8:30:00 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Bagai Shaun

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      7/3/25 4:45:33 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Agah Ramtin

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      7/3/25 4:45:34 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Clinical Officer Gentry Leesa

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      7/3/25 4:45:31 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital initiated coverage on RenovoRx with a new price target

      Roth Capital initiated coverage of RenovoRx with a rating of Buy and set a new price target of $16.00

      11/1/21 11:49:10 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on RenovoRx with a new price target

      Maxim Group initiated coverage of RenovoRx with a rating of Buy and set a new price target of $15.00

      10/6/21 8:24:28 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Financials

    Live finance-specific insights

    See more
    • RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

      Q1 2025 RenovoCath® Revenues of ~$200,000, Exceeding Expectations and Anticipated to Continue Growing Sequentially with New Customer Purchase Orders and Reorders Cash on Hand of $14.6 Million Anticipated to Fully Fund both RenovoCath Commercialization Scale-up and Continued Progress Towards the Completion of the Ongoing Phase III TIGeR-PaC Clinical Trial Completion of the TIGeR-PaC Clinical Trial Enrollment and Review of Second Interim Analysis by Data Monitoring Committee on Target for 2025 Company to Host Conference Call at 4:30 p.m. ET RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializ

      5/15/25 4:05:00 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

      RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced it will host its first quarter 2025 financial results conference call on May 15th, 2025, at 4:30 p.m. ET. Additional details will be available in the Investor Relations section of the Company's website at https://ir.renovorx.com/. Event: RenovoRx First Quarter 2025 Financial Results Conference Call Date: Thursday, May 15, 2025 Time: 4:30 p.m. ET Live Call: 1-877-407-4018 (U.S. Toll Free) or 1-201-689-8471 (International) Webcast:

      5/1/25 8:30:00 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by RenovoRx Inc. (Amendment)

      SC 13G/A - RenovoRx, Inc. (0001574094) (Subject)

      2/14/23 4:51:34 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by RenovoRx Inc.

      SC 13G - RenovoRx, Inc. (0001574094) (Subject)

      4/14/22 2:24:24 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by RenovoRx Inc.

      SC 13G - RenovoRx, Inc. (0001574094) (Subject)

      2/14/22 6:33:04 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care